



**UNIVERSIDAD NACIONAL MAYOR DE SAN MARCOS**

**FACULTAD DE MEDICINA HUMANA**

**UNIDAD DE POST GRADO**

**Dislipidemia durante la terapia antirretroviral en pacientes con infección por VIH/SIDA atendidos en el HNERM, 2000 – 2003.**

**Bibliografía**

**TRABAJO DE INVESTIGACIÓN**

Para optar el Título de Especialidad en Medicina de Enfermedades Infecciosas y Tropicales

AUTOR

**Miguel Villegas Chiroque  
Jorge Eduardo Mezarina Valverde**

LIMA – PERÚ  
2004

## REFERENCIAS BIBLIOGRAFICAS

1. **ONUSIDA / OMS.** Situación e la epidemia de SIDA, diciembre de 2003.  
ONUSIDA /OMS. [www.unaids.org](http://www.unaids.org).
2. **OGE / MINSA.** La situación del VIH en el Perú. Boletín epidemiológico  
Enero 2004. OGE/ MINSA [www.oge-minsa.com.pe](http://www.oge-minsa.com.pe).
3. **VIA LIBRE.** Información estadística de casos de SIDA Enero 2004.  
ONG Vía Libre Lima Perú. [www.vialibre.com.pe](http://www.vialibre.com.pe).
4. **Alcamí J, Rulas J, Bermejo M, Beltran M, Sanchez-Palomin S.**  
Inmunopatología del SIDA. *Med Integral* 2001; 10: 428-42.
5. **Palella FJJ, Delaney KM, Moorman AC, et al.** Declining morbidity and  
mortality among patients with advance human immunodeficiency virus  
infection *N Eng J Med* 1998; 338: 853-60.
6. **Hirschel B, Oprovil M.** The year in review: antiretroviral treatment.  
*AIDS* 1999; 13 (suppl A): S177-87.
7. **Briones C, Soriano V.** Inhibidores de la proteasa de VIH: pros y  
contras. *Med Clin (Barc)* 1999; 112: 702-5.

8. **Carr A, Cooper D.** Adverse effects of antiretroviral therapy. *Lancet* 2000; 356: 1423-30.
9. **Martinez E, Macrof A, Garcia-Viejo M, et al.** Risk of lipodystrophy in HIV1-infected patients treated with protease inhibitors: a prospective cohort study. *Lancet* 2001; 357: 592-8.
10. **Smith KY.** Selected metabolic and morphologic complications associated with HAART. *J Infect Dis* 2002; 185 (supp 2): S123-7.
11. **Dube M, Fenton M.** Lipid abnormalities. *Clin Infec Dis* 2003; 36 (suppl 2): S79-83.
12. **Mooser V, Carr A.** Antiretroviral therapy –associated hyperlipidaemia in HIV disease. *Curr Opin Lipidol* 2001; 12:313-9.
13. **Van der Valk M, Reiiss P.** Lipid profiles associated with antiretroviral drug choice. *Curr Opin Infec Dis* 2003; 16: 19-23.
14. **Periard D, Telenti A, Sudre P, et at.** Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Swiss HIV Cohort Study. *Circulation* 1999; 100: 700-5.
15. **Egger M, Junghans C, Friis-Moller N, Lundgreen J.** Highly active antiretroviral therapy and coronary heart disease: the need for perspective. *AIDS* 2001; 15 (Supp5): S193-201.
16. **Dominiczak MH.** Hyperlipidaemia and cardiovascular disease. *Curr Opin Lipidol* 2002; 13: 449-51.

17. **Bozzete S, Ake FC, Tam HK, Chang SW, Louis TA.** Cardiovascular and Cerebrovascular Events in Patients Treated for Human Immunodeficiency Virus Infection. *NEJM* 2003, 348:702-10.
18. **Baron RB.** Anomalías de los lípidos. En *Diagnóstico Clínico y tratamiento de Tierney* , 38 edic, edit Manual Moderno, México; 2003: 1219-30.
19. **Sellmeyer DE, Grunfeld C.** Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. *Endocrinol Rev* 1996; 17; 518-32.
20. **Gutierrez-Rodríguez R, Campa A, Shor-Posner G, Baum MK.** Estado del metabolismo de los lípidos en la infección por VIH-1 y SIDA. *Diagnóstico* 1998, 37: 336-43.
21. **Mildvan D, Machado SG, Wilets I, et al.** Endogenous interferon and triglycerides concentrations to assess response to zidovudina in AIDS and advanced AIDS. related complex. *Lancet* 1992; 339: 453- 6.
22. **Carr A, Samaras K, Thorisdottir A, et al.** Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. *Lancet* 1999 ; 353: 2093-9.

23. **Purnell J, Zambon A, Knoop RH, et al.** Effects of ritonavir on lipids and post-heparin lipase activities in normal subjects, *AIDS 2000*, 14: 51-57.
24. **Carr A, Sammaras K, Chisholm D, Cooper D.** Pathogenesis of HIV-1 protease inhibitor- associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. *Lancet 1998*, 352: 1881-3.
25. **Chene G, Angelini E, Cotte L, et al.** Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in HIV – infected patients. *Clin Infect Dis 2002*, 34: 649-57.
26. **Drechsler H, Powderly WG.** Switching effective antiretroviral therapy: a review. *Clin Infect Dis 2002*; 35: 1219-30.
27. **Negredo E, Ribalta J, Paredes R, et al.** Reversal of atherogenic lipoprotein profile in HIV.1 infected patients with lipodystrophy after replacement protease inhibitor by Nevirapine. *AIDS 2002*; 16: 1383-89.
28. **Estrada V, P de Villar NG, Martines T, Gonzáles A, Fernández C, Serrano-Ríos M.** Long-term metabolic consequences of switching from protease inhibitors to Efavirenz in therapy for HIV-infected patients with lip atrophy. *Clin Infect Dis 2002*, 35: 69-76.
29. **ESSALUD.** Manual de Normas y procedimientos del programa de control de ITS-VIH / SIDA. EsSalud, Lima 2002, 1-72.

30. **ESSALUD**. Protocolo para el tratamiento antirretroviral de los pacientes adultos con infección por VIH /SIDA. EsSalud, Lima 1999, 1-24.
31. **ESSALUD**. Protocolo de tratamiento antirretroviral para pacientes adultos con infección por VIH /SIDA. EsSalud, Lima 2002, 1-23.
32. **NCEP**. Executive summary ATP III. *Jama* 2001, 285: 2486-97.
33. **MINSA**. Guía nacional de atención integral del paciente con infección VIH/ SIDA. MINSA, Lima, 1999, 1-128.
34. **Mauss S, Stechel J, Willer R, Schumutz G, Berger F, Richter W**. Differentiating hyperlipidaemia associated with antiretroviral therapy. *AIDS* 2003, 17: 189-94.
35. **Stein JH, Klein MA, Bellenhumeur JL, et al**. Use of HIV-1 Protease Inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. *Circulation* 2001, 104: 257-62.
36. **Hirsch HH, Battegay M** Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management. *Infection* 2002, 30: 293-8.
37. **Penzak SR, Chuck SK**. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. *Scand J Infect Dis* 2000; 32: 111-32.

38. **Lenhard JM, Croom DK, Weiel JE, Winegar D.** HIV protease inhibitors stimulate hepatic triglyceride synthesis. *Arterioscler Thromb Vasc Biol* 2000; 20: 2625-9.
39. **Saves M, Raffi F, Capeau J, et al.** Factors related to lipodystrophy and metabolic alterations patients with HIV infection receiving HAART. *Clin Infect Dis* 2002; 34: 1396-405.
40. **Dybul M, Fauci AS, Bartlett J, et al .** Guidelines for the using of antiretroviral agents among HIV-infected adults and adolescents. *Ann Int Med* 2002; 137: 381-433.
41. **Rivera R, Bracjkovich IE, Lilue M, Kaswan E, et al.** Dislipidemia en infección por VIH en diferentes estadios de la enfermedad. Estudio prospectivo en 41 pacientes. *Rev de la Soc Venezol de Med Int* 2000.